Sexual Intimacy Could Get Back to Normal for Older Women Using PRO 140

According to a recent CDC report: women who no longer worry about getting pregnant may be less likely to use a condom or practice safe sex. They are more likely than men to become HIV infected through unprotected heterosexual intercourse. The stigma of being HIV infected may negatively affect their quality of life, self-image, and behavior. Protecting that quality of life may also prevent them from disclosing their HIV status and seeking HIV care.

"The return to a normal life has become a possibility for HIVers as reports on the PRO 140 FDA studies continue to attract attention. So powerful is one weekly subcutaneous 350mg dose of our PRO 140 that HIV patients in a monotherapy study have had suppressed viral loads for the last 12 months," said Nader Pourhassan, CEO, CytoDyn Inc. "That means one whole year with almost zero chance of infecting others on just one dose of PRO 140 a week. The sometimes self-inflicted stigma of being infected with HIV begins to wane."

When approved by the FDA, HIV patients no longer need to take 4, 5, 6 pills -- every day -- for the rest of their lives. The long-suffering HIVers can look forward to just one dose a week of PRO 140 to completely suppress their viral loads.

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T-cells which prevents viral entry.

Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from six Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV.

For more information on the Company, please visit www.cytodyn.com.